FindTrial
Sign In

Z-206 Phase III Clinical Trial - Investigation on the remission-maintaining effect in patients with ulcerative colitis in remission phase -

Z-206 Phase III Clinical Trial - Investigation on the remission-maintaining effect in patients with ulcerative colitis in remission phase -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220177
Enrollment
Unknown
Registered
2005-11-22
Start date
2005-11-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with ulcerative colitis in remission phase

Interventions

investigational material(s) Generic name etc : Z-206 INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investigat

Sponsors

ZERIA Pharmaceutical Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with ulcerative colitis in remission phase who are defined to show Ulcerative Colitis-Disease Activity Index (UC-DAI) score of not less than 2 and bloody stool score of 0.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Non-incidence of bloody stool—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026